Dr. Jyothis George serves as the Chief Medical Officer of NodThera, driving the clinical acceleration of oral small molecules that quell chronic inflammation to reduce cardiovascular risk and to improve metabolic and brain health. A pioneer in NLRP3 inflammasome inhibition, NodThera is currently running the industry’s largest and longest clinical program in this class. With multiple clinical readouts for NodThera’s assets in 2026, Jyothis is laser-focused on accelerating the path to approval, leveraging decades of global leadership in cardiometabolic drug development and
regulatory strategy.
Blockbuster CardioMetabolic Development
Prior to NodThera, Jyothis held pivotal executive roles at some of the world's leading pharmaceutical organizations:
Amgen: As Global Medical Vice President, he led the General Medicine Therapeutic Area, overseeing research, development and delivery across
CardioMetabolism, Bone, Neurology, and Nephrology with multiple blockbusters including Evolocumab (Repatha®).
Novo Nordisk: As Corporate Vice President, he successfully delivered major regulatory studies for assets including semaglutide (Wegovy®) and
launched global educational platforms like ObesityME.
Boehringer Ingelheim: As Global Head of Clinical Development and Medical Affairs (Cardiometabolism), he directed the teams for empagliflozin
(Jardiance®)—the first diabetes treatment to earn an FDA cardiovascular mortality indication—and linagliptin (Trajenta®).
Clinical & Academic Excellence
Jyothis has served on the steering committees of six major cardiovascular outcomes trials and has authored over 100 peer-reviewed publications. He is the founder of the CardioMetabolic Health Foundation, a non-profit dedicated to personalizing care at scale. He serves as Visiting Professor of Cardiometabolic Medicine at the University of Oxford.